semaglutide effects on kidneys and kidney disease FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in Ozempic (Semaglutide): GLP-1 receptor agonist

Luci S, Hirche F, Eder K: Fasting and caloric restriction increases mRNA concentrations of novel organic cation transporter-2 and carnitine concentrations in rat tissues

With proper dosing and time, most patients ultimately experience the appetite-regulating benefits these medications can provide

In patients who do not respond to treatment, the value of continuous enteral feeding and especially of surgical re-intervention and pancreatic resection is uncertain (statements 5658 and 6062) and a conservative, non-surgical approach is recommended (statement 59)

See related article by Breitzig et al G lucagon-like peptide-1 receptor agonists (GLP-1 RAs) mimic the physiological effects of native incretins insofar as they facilitate glucose-stimulated insulin secretion, decrease glucagon synthesis and release, slow gut motility, and reduce appetitive drive